A new study has considered some of the potential benefits and risks of glucagon-like peptide 1 receptor agonists (GLP-1RAs), which are increasingly being used to treat diabetes and obesity.
This study, published Monday in Nature Medicine, used US Department of Veterans Affairs databases to build a cohort of people with diabetes who started treatment with GLP-1Ras and compared them to those who began taking sulfonylureas, dipeptidyl peptidase 4 (DPP4) inhibitors or sodium−glucose cotransporter-2 (SGLT2) inhibitors, a control group composed of an equal proportion of people initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors, and a control group who continued with non-GLP-1RA antihyperglycemics (usual care). -
Leading on-market GLP-1Ras include semaglutide - Novo Nordisk’s (NOVN: VX) drug marketed as Wegovy and Ozempic, and Eli Lilly’s (NYSE: LLY) tirzepatide, which is branded as Mounjaro and Zepbound.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze